Shete PB, Murrill MT, Tatum KM, Ahmed A, Aiona K, Aldous JL, Flood J, Haas MK, Narita M, Pettit AC, Séraphin MN, Cattamanchi A, Ayers TL. Identifying Gaps in Tuberculosis Preventive Care for Non-U.S.-born Persons at Community Health Clinics in the United States. Open Forum Infect Dis. 2025 Sep 24;12(10):ofaf589. doi: 10.1093/ofid/ofaf589. PMID: 41103780; PMCID: PMC12527284.
Wendorf KA, Armitige L. Improving Tuberculosis Infection Treatment Completion among Pregnant and Postpartum Women. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. 2025 Jun. doi: 10.1016/j.jctube.2025.100543.
Murrill MT, Salcedo K, Tschampl CA, Ahamed N, Coates ES, Flood J, Wegener DH, Shete PB. Policy Impediments to Tuberculosis Elimination: Consequences of an Absent Medicare National Coverage Determination for Tuberculosis Prevention. J Immigr Minor Health. 2025 Jun;27(3):403-408. doi: 10.1007/s10903-025-01674-1. Epub 2025 Mar 5. PMID: 40131575; PMCID: PMC12037422.
Saukkonen JJ, Duarte R, Munsiff SS, Winston CA, Mammen MJ, Abubakar I, Acuña-Villaorduña C, Barry PM, Bastos ML, Carr W, Chami H, Chen LL, Chorba T, Daley CL, Garcia-Prats AJ, Holland K, Konstantinidis I, Lipman M, Battista Migliori G, Parvez FM, Shapiro AE, Sotgiu G, Starke JR, Starks AM, Thakore S, Wang SH, Wortham JM, Nahid P. Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med. 2025 Jan;211(1):15-33. doi: 10.1164/rccm.202410-2096ST. PMID: 40693952; PMCID: PMC11755361.
Bertumen JB, Pascopella L, Han E, Glenn-Finer R, Wong RJ, Chitnis A, Jaganath D, Jewell MP, Gounder P, McElroy S, Stockman L, Barry P. Expected vs Reported Chronic Hepatitis B Infection Cases in Persons with Active Tuberculosis - California, 2016-2020. J Public Health Manag Pract. 2024 Sept-Oct 01;30(5):728-732. doi: 10.1097/PHH.0000000000001955. Epub 2024 Jul 22.PMID: 38985652.
Bertumen JB, Pascopella L, Han E, Glenn-Finer R, Wong RJ, Chitnis A, Jaganath D, Jewell M, Gounder P, McElroy S, Stockman L, Barry P. Epidemiology and Treatment Outcomes of Tuberculosis with Chronic Hepatitis B Infection-California, 2016-2020. Clin Infect Dis. 2024 Mar 26:ciae169. doi: 10.1093/cid/ciae169. Epub ahead of print. PMID: 38531668.
Miyakawa R, Louie J, Keh C, Chen L, Javid B, Ernst JD, Goswami N, Chow FC. A teenage girl with altered mental status and paraparesis. J Clin Tuberc Other Mycobact Dis. 2024 Mar 1;35:100425. doi: 10.1016/j.jctube.2024.100425. PMID: 38468819; PMCID: PMC10926304.
Ayers T, Hill AN, Raykin J, Mohanty S, Belknap RW, Brostrom R, Khurana R, Lauzardo M, Miller TL, Narita M, Pettit AC, Pyan A, Salcedo KL, Polony A, Flood J. Comparison of Tuberculin Skin Testing and Interferon-γ Release Assays in Predicting Tuberculosis Disease. JAMA Netw Open. 2024;7(4):e244769. doi:10.1001/jamanetworkopen.2024.4769
Nabity SA, Agraz-Lara R, Bravo A, Benjamin R, Fong V, Lam CK, Keh C, Mase S, Flood J. Notes from the Field: Supply Interruptions of First- and Second-Line Oral Drugs to Treat Tuberculosis During the Previous 12 Months - California, January-March, 2023. MMWR Morb Mortal Wkly Rep. 2024 Jan 5;72(5253):1390-1391. doi: 10.15585/mmwr.mm725253a2. PMID: 38175801.
Han E, Nabity SA, Dasgupta-Tsinikas S, Guevara RE, Moore M, Kadakia A, et al. Tuberculosis Diagnostic Delays and Treatment Outcomes among Patients with COVID-19, California, USA, 2020. Emerg Infect Dis, 2024.;30(1):136-140. https://doi.org/10.3201/eid3001.230924
Katrak S, Wang R, Barry P. Costs of treating multidrug-resistant TB in California in 2022. Int J Tuberc Lung Dis. 2023 Nov 1;27(11):864-866. doi: 10.5588/ijtld.23.0150. PMID: 37880888; PMCID: PMC10599414.
Frazier C, Nabity SA, Flood J. Incidence of TB disease among persons who use drugs in California. Int J Tuberc Lung Dis. 2023 Oct 1;27(10):781-783. doi: 10.5588/ijtld.23.0228. PMID: 37749841; PMCID: PMC10519387.
Nabity SA, Marks SM, Goswami ND, Smith SR, Timme E, Price SF, Gross L, Self JL, Toren KG, Narita M, Wegener DH, Wang SH; National Tuberculosis Controllers Association/CDC TB-COVID-19 Collaboration1. Characteristics of and Deaths among 333 Persons with Tuberculosis and COVID-19 in Cross-Sectional Sample from 25 Jurisdictions, United States. Emerg Infect Dis. 2023 Oct;29(10):2016-2023. doi: 10.3201/eid2910.230286. Epub 2023 Aug 30. PMID: 37647628; PMCID: PMC10521611.
Louie JK, Keh CE. Latent Tuberculosis Infection Treatment: Still a Long Road Ahead. Clin Infect Dis. 2023 Jul 26;77(2):295-297. doi: 10.1093/cid/ciad251. PMID: 37125504.
Shete PB, Tang AS, Flood J. Screening for Latent Tuberculosis Infection Among Non-US-Born Adults in the US: A Path Toward Elimination. JAMA. 2023 May 2;329(17):1457-1459. doi: 10.1001/jama.2023.4967. PMID: 37129665.
Tang AS, Mochizuki T, Dong Z, Flood J, Katrak SS. Can Primary Care Drive Tuberculosis Elimination? Increasing Latent Tuberculosis Infection Testing and Treatment Initiation at a Community Health Center with a Large Non-U.S.-born Population. J Immigr Minor Health. 2023 Aug;25(4):803-815. doi: 10.1007/s10903-022-01438-1. Epub 2023 Jan 18. PMID: 36652151; PMCID: PMC9847435.